Edwards Lifesciences (NYSE: EW) today announced new data demonstrating long-term benefits with its Sapien heart valve system.

Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data, which showed superior clinical ...

Investing.com -- Edwards Lifesciences (NYSE:EW) stock rose 4.5% following the presentation of new data showing long-term benefits and valve performance of its SAPIEN 3 TAVR.

Five-year data from the PARTNER 3 trial showed that among low-risk patients with severe, symptomatic aortic stenosis, ...

Edwards Lifesciences Corp. (($EW)) announced an update on their ongoing clinical study. Edwards Lifesciences Corp. is collaborating with World ...

Edwards Lifesciences Corp. (($EW)) announced an update on their ongoing clinical study. Study Overview: Edwards Lifesciences Corp. is conducting ...

Over the last two decades, Edwards Lifesciences has demonstrated that it knows how to maintain leadership through innovation of tissue heart valves. Edwards remains the dominant force in surgical ...

IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences (EW) announced today that the U.S. Food and Drug Administration (FDA) has approved its transcatheter aortic valve replacement (TAVR) therapy, the ...

The companies have teamed to develop an alternative to TAVR that combines the benefits of a less-invasive procedure with the ...

Edwards Lifesciences Corp.’s posted fourth quarter results slightly ahead of expectations, but indicated that the first quarter of 2025 might not be as bright. The company expects growth for both its ...

Edwards Lifesciences EW has announced one-year, real-world data on its SAPIEN 3 Ultra RESILIA valve at the PCR London Valves 2024. These data add to the extensive body of evidence on the company’s ...